Research Papers:
Promoting progression and clinicopathological significance of NEAT1 over-expression in bladder cancer
Metrics: PDF 1723 views | HTML 1373 views | ?
Abstract
Chen XianGuo1, Hao ZongYao1, Zhou Jun1, Fan Song1, Luo GuangYue1, Zhang LiGang1, Zhang KaiPing1, Zhang YangYang1, Liang ChaoZhao1
1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, PR China
Correspondence to:
Liang ChaoZhao, email: [email protected]
Keywords: NEAT1, bladder cancer, long noncoding RNA, clinical pathologic
Received: November 07, 2015 Accepted: May 28, 2016 Published: June 15, 2016
ABSTRACT
Bladder cancer was the most important reason of cancer-related death around the world, and urgently requires new therapeutic methods targeting the malignant tumor. There are many reports that the long noncoding RNAs are participated in different cancers, however, limited data are found between the long noncoding RNAs and bladder cancer. Previous studies have indicated that lncRNAs play vital roles in gene regulatory processes which could influence carcinoma progression.It is well known that lncRNAs can’t code proteins, however, controlling transcription was found in the life process.In the current study,we firstly reported that NEAT1 was consistently up-regulated in bladder cancer tissues compared to the matched tissues and bladder cancer cell lines compared to the normal bladder epithelial cell and the expression level of the NEAT1 in bladder cancer tissues is closely related to its clinical pathologic grade and TNM phase. Cell proliferation inhibition, cell migration suppression and apoptosis induction were detected by knockdown NEAT1. However, it is imperative that this hypothesis is further tested through. In conclusion, NEAT1 may play oncogenic roles and can be used as a therapeutic target for treating human bladder cancer. Our finding provides a new insight into the role of the LncRNA NEAT1 in the bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10084